Zegerid deal solidifies
This article was originally published in The Tan Sheet
A Santarus license agreement with Schering-Plough for OTC commercialization rights to its immediate-release omeprazole product Zegerid is now effective, as the waiting period required under antitrust law has expired, the firm announces Nov. 21. Santarus expects the proton pump inhibitor's quick action to give it a competitive advantage over P&G's Prilsoec OTC if S-P can gain approval for an Rx-to-OTC switch. The agreement includes a $15 mil. upfront license fee and up to $65 mil. in additional milestone payments (1"The Tan Sheet" Oct. 23, 2006, p. 3)...
You may also be interested in...
Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.